Strongest evidence yet that Ozempic and Wegovy reduce alcohol intake
New ScientistFeb 12
Weight-loss Drug Shows Promise in Reducing Alcohol Consumption
story
Above: A man injects the drug Ozempic into his stomach with a syringe to trat type 2 diabetes on Jan. 31, 2025. Image copyright: Roberto Pfeil/picture alliance via Getty Images
The Facts
A study has found that semaglutide, a drug originally developed to treat type 2 diabetes and sold by Novo Nordisk as brands Wegovy and Ozempic, cut alcohol consumption in patients by about 40% and reduced the desire to drink.
Nearly 40% of people in the semaglutide group reported no heavy drinking days in the last month of treatment, compared with 20% in the placebo group, demonstrating significant behavioral changes, according to the study.
The research, conducted by scientists of University of North Carolina School of Medicine, observed 48 people with a drinking problem, and additionally showed that the use of semaglutide reduced participants' rate of cigarette smoking significantly.
The Spin
Narrative A
The magnitude of semaglutide's effects on alcohol consumption appears stronger than existing medications for alcohol use disorder, even at the lowest clinical doses, suggesting tremendous potential for treating addiction. The drug's ability to reduce both alcohol consumption and cravings could revolutionize treatment options for millions struggling with alcohol dependence. The results demonstrate a clear pathway for new therapeutic approaches.
Narrative B
The study's small sample size, short duration, and limited participant demographics cap the broader applicability of these findings. The research excluded individuals who typically seek treatment for severe alcohol use disorder, and potential side effects still need further investigation. Existing approved medications for alcohol use disorder should remain the primary treatment option until more comprehensive research is completed.
